Galapagos spinout Coultreon raises $125M for new take on SIK inhibition

Pierre Raboisson, Coultreon Biopharma CEO April 28, 2026 07:00 AM EDT FinancingStartups Gala­pa­gos spin­out Coul­tre­on rais­es $125M for new take on SIK in­hi­bi­tion Kyle LaHucik Biotech Correspondent Coul­tre­on Bio­phar­ma has patched to­geth­er $125 mil­lion from some of the largest biotech in­vestors in the US and Eu­rope in a bid to join the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER